Clinical Research
Filter News
Found 105,297 articles
-
Anaeropharma Science Signs Collaborative Research Agreement with Chugai on Creation of Novel Oncology Drugs Using Bifidobacterium
10/22/2018
Anaeropharma Science Inc. announced on October 22 that Anaeropharma Science and Chugai Pharmaceutical Co., Ltd. headquartered in Tokyo (hereinafter "Chugai") have concluded a collaborative research agreement concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, "in situ Delivery and Production System" (hereinafter "i-DPS").
-
Aortica™ Corp. Announces Publication of Successful Results Demonstrating Simplification of Fenestrated EVAR Using AortaFit™ Automated Case Planning Software
10/22/2018
Dr. Benjamin Starnes’ PS-IDE Study Results published in Journal of Vascular Surgery
-
Lupus Foundation of America Studies Reveal Disparities in Care of Minority Patients and the Role of Primary Care Providers in Lupus Care Management
10/21/2018
In two first of their kind research studies, the Lupus Foundation of America (LFA) has identified needs in lupus provider education and care practices for minority patients.
-
Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer
10/20/2018
Results Presented at the ESMO 2018 Congress (European Society for Medical Oncology) and Simultaneously Published in The New England Journal of Medicine
-
Bioelectronic medicine treatment effective for lupus, pilot clinical trial shows
10/20/2018
Results shared at ACR/ARHP annual meeting highlight non-invasive therapy reduces pain and fatigue associated with lupus
-
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
10/20/2018
Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC).
-
Varian Forms FlashForward Consortium to Study Ultra-high Dose Rate Cancer Treatments with Protons
10/20/2018
To expand the encouraging preclinical and translational research already conducted by Varian (NYSE: VAR) and two of its clinical partners, Maryland Proton Treatment Center and Cincinnati Children's/UC Health Proton Therapy Center,
-
October 19 Research Roundup: Dementia, Frankenstein Proteins, and Epigenetic Sperm Changes
10/19/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).
-
Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant pros...
-
Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting
10/19/2018
MSI-High Status Now Part of Guardant360® Assay
-
CDC Prevention Epicenters Program-Funded Study Proves Enhanced UVC Disinfection Reduces Microbial Contamination, Decreasing Patient Colonization and Infection
10/19/2018
BETR-Disinfection researchers conclude addition of UVC disinfection is significantly superior to manual disinfection alone
-
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
10/19/2018
At the three-year mark, patients receiving TREMFYA® in clinical studies continue to show stably maintained PASI 90 and IGA 0/1 responses
-
One in Six Patients Could be Denied Insurance Coverage in an Emergency if Anthem Policy Continues to Spread, New Study Shows
10/19/2018
A new study in JAMA Network Open underscores the risk to patients if the Anthem Blue Cross Blue Shield policy to deny emergency coverage based largely on a patient's diagnoses after a visit, is adopted nationwide.
-
InDex Pharmaceuticals Publishes Post-hoc Analysis of the COLLECT Study
10/19/2018
InDex Pharmaceuticals Holding AB today announced the publication of a post-hoc analysis of COLLECT study data.
-
GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress
10/19/2018
GRAIL, Inc. today announced that new data from the Circulating Cell-free Genome Atlas (CCGA) study will be presented by Minetta Liu, MD, Research Chair and Professor, Department of Oncology, Mayo Clinic, in an oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19 – 23 in Munich, Germany.
-
Cannabis Market Continues to Grow on Global Legalization Efforts
10/19/2018
According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023 while growing at a CAGR of 37% during the forecast period
-
Researchers at the University of Cambridge published research in the journal Nature Communications that suggests spontaneous DNA mutations may cause the majority of dementias.
-
AbbVie Invests $100 Million in Morphic Therapeutics to Develop Integrin Inhibitors for Fibrotic D...
10/18/2018
Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications. -
Another scientific paper has been retracted by the New England Journal of Medicine. The noted journal said it retracted a paper on evidence of human lung stem cells following an investigation that revealed images used in the article had been manipulated.